Focus Stocks》Dayan Biomedical*: Profit hits record high, stock price rebounds

The after-tax net profit of health food manufacturer Dayan Biomedical* (7780) in the first three quarters was 344 million yuan, an annual increase of 61.13%, which has exceeded the full-year revenue and profit in 2025. (Provided by Dayan Biomedical)

[Reporter Yang Yamin/Taipei Report] The cumulative revenue of health food factory Dayan Biomedical* (7780) in the first ten months was 1.911 billion yuan, an annual increase of 38.94%. The after-tax net profit in the first three quarters was 344 million yuan, an annual increase of 6.113%. %, has exceeded the full-year revenue and profit in 2025, with earnings per share of 0.43 yuan. The stock price rebounded today. As of 10:40, the stock price was temporarily reported at 15.05 yuan, an increase of 3.79%, with a trading volume of 797 contracts.

Dayan Biomedical's revenue and profit both hit record highs, mainly due to the solid sales momentum of core products, the effectiveness of new product strategies and the continued growth of overseas markets. As the fourth quarter enters the annual e-commerce sales season, important shopping periods such as Double 11 will continue to appear, which is expected to further inject revenue and continue the operational growth momentum.

Lin Dongqing, chairman of Dayan Biomedical, said that the company continues to develop core categories such as fish oil, lutein and probiotics, and expands its product line through differentiated formulas and dosage forms. In the Taiwan market, the company will continue to deepen brand management and channel layout, and gradually expand the scale of operations in overseas markets such as Japan to lay the foundation for mid- to long-term growth.